Distinguished Speakers

Ambar Ahmed, Senior Scientific Manager, Oncology Translational Sciences, AstraZeneca

John L. Allinson, FIBMS, Vice President, Biomarker Services, Biologics Development Services, Tampa Bay

Robert A. Anders, MD, PhD, Associate Professor, Pathology; Co-Director, Tumor Microenvironment Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University

Brittany Bahamon, Scientist I, Translation & Biomarker Research, Takeda Pharmaceuticals, Inc.

Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories

Robert A. Beckman, MD, Professor, Oncology, Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center

Michael J. Benecky, PhD, Senior Director, Global Regulatory Affairs, Precision and Digital Medicine, R&D Chief Regulatory Office, GlaxoSmithKline

Peter Bergethon, MD, Vice President, Quantitative Medicine and Clinical Technologies, Biogen

Erhan Bilal, PhD, Researcher, IBM T.J. Watson Research/Computational Biology Center

Marijo Bilusic, MD, PhD, Associate Research Physician, National Cancer Institute, National Institutes of Health

Darrell R. Borger, PhD, Scientific Director, Immuno-Profiling Laboratory; Director, Translational Research/Biomarker Laboratory, Massachusetts General Hospital Cancer Center

Tullia Bruno, PhD, Research Assistant Professor, Immunology, University of Pittsburgh

Michael E. (Ted) Burczynski, PhD, PPM Expert, Director, Personalized & Predictive Medicine, Analytics & Big Data, Teva Pharmaceuticals

Amanda J. Centi, PhD, Research Program Manager, Connect Health Innovation, Partners HealthCare

Yu-Feng Yvonne Chan, MD, PhD, Associate Professor, Genetics and Genomics Sciences & Emergency Medicine; Director, Center for Digital Health, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai

Pratip Chattopadhyay, PhD, Associate Professor, Pathology; Director, Precision Immunology Incubator, Isaac and Laura Perlmutter Cancer Center, New York University Langone Medical Center

Carolyn Compton, MD, PhD, Professor, Life Science, Arizona State University; CMO, ASU Complex Adaptive Systems Institute; CMO, National Biomarker Development Alliance

Mark E. Curran, PhD, Vice President and Head of Companion Diagnostics, Janssen Immunology

Viswanath Devanarayan, PhD, Global Head of Statistics & Data Sciences, Charles River Laboratories

Kenneth Emancipator, MD, Executive Medical Director and Head of Companion Diagnostics, Merck & Co.

Steven Fling, PhD, Senior Staff Scientist, Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center; Director, Cancer Immunotherapy Trials Network Immune Monitoring Laboratory

Shirin Khambata Ford, PhD, Global Head, Biomarkers and Diagnostics, Executive Director, Oncology Global Medical Affairs, Merck

Bernard A. Fox, PhD, Harder Family Chair for Cancer Research, Member and Chief, Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Portland Medical Center; CEO, UbiVac

Mark Frasier, PhD, Senior Vice President, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research

Tim Fugmann, PhD, Head, Precision Medicine, Philochem AG

Jianjun Gao, MD, PhD, Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center

Arnold B. Gelb, MD, Senior Director, Clinical Development, Ziopharm Oncology

Marios Giannakis, MD, PhD, Medical Oncologist & Clinical Investigator, Dana-Farber Gastrointestinal Cancer Treatment Center; Researcher, Broad Institute of MIT and Harvard

Sacha Gnjatic, PhD, Associate Professor, Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai

Christian Gossens, PhD, MBA, Global Head, Early Development Workflows, pRED Informatics, Roche Pharmaceutical Research and Early Development

Daniel Grant, PhD, Director, Early Development Lead, Novartis

George A. Green, IV, PhD, Head, Pharmacodiagnostics, Bristol-Myers Squibb

Abdel B. Halim, PharmD, PhD, DABCC, FAACC, Vice President, Translational Medicine, Biomarkers & Diagnostics, Celldex Therapeutics

Gerald Hall, PhD, Principal Research Scientist, Experimental and Translational Immuno-Oncology: Biomarkers, Eli Lilly

Samir Hanash, MD, PhD, Director, McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center

Brent A. Hanks, MD, PhD, Assistant Professor, Cancer Immunology/Immunotherapy, Duke Cancer Institute

Christopher M. Hartshorn, PhD, Program Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health

Elena Izmailova, PhD, Senior Director, Novel Data Streams and Devices, Data Science Institute, Takeda Pharmaceuticals International, Inc.

Vladimir Jankovic, MD, Director, Precision Medicine, Early Clinical Development & Experimental Sciences, Regeneron

Filip Janku, MD, PhD, Associate Professor, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center

Sarah Javaid, PhD, Associate Principal Scientist, Merck

John Milburn Jessup, MD, Scientific Director, Precision Cancer Care Program, Inova Schar Cancer Institute; Professor, Systems Biology, Krasnow Institute of Advanced Study, George Mason University

Shidong Jia, PhD, Founder & CEO, Predicine

Bruce E. Johnson, MD, Professor of Medicine, Harvard Medical School

Karin Jooss, PhD, CSO, Gritstone Oncology

Pawel Kalinski, MD, PhD, Professor, Oncology, Vice-Chair, Translational Research, Roswell Park Cancer Institute

Maria Karasarides, PhD, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals

Daniel Karlin, MD, Head, Experimental Medicine, Informatics & Regulatory Strategy, Pfizer

Mark Lackner, PhD, Director and Principal Scientist, Genentech

Marc Ladanyi, MD, William J. Ruane Chair in Molecular Oncology, Molecular Diagnostics Service and Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

Rebecca Leary, PhD, Lab Head, Next Generation Diagnostics, Novartis Institutes for BioMedical Research

Joel Lefferts, PhD, Assistant Professor, Pathology, Assistant Director, Clinical Genomics and Advanced Technology (CGAT), Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center

Mingjie Liu, PhD, Clinical Biomarker Lead, Translational Science, Oncology Business Group, Eisai

Andrey Loboda, PhD, Director, Genetics and Pharmacogenomics, Merck

Christina Lockwood, PhD, Associate Professor, Director, Genetics and Solid Tumors Laboratory, University of Washington

Rajyalakshmi (Raja) Luthra, PhD, Director, Molecular Diagnostics Laboratory; Director, Molecular Genetics Pathology Fellowship Program; Professor, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center

Kathleen M. Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute

Christopher Major, PhD, Scientific Director, Diagnostic Development, Janssen

Rajarsi Mandal, MD, Head and Neck Surgical Oncology Fellow, Memorial Sloan Kettering Cancer Center

Sanjeev Mariathasan, PhD, Senior Scientist, Oncology Biomarker Department, Genentech

James R. Mault, MD, FACS, Senior Vice President and CMO, Qualcomm Life

Jennifer J.D. Morrissette, PhD, Scientific Director, Clinical Cancer Cytogenetics, Clinical Director, Center for Personalized Diagnostics, University of Pennsylvania

Carol Anne Ogden, PhD, Senior Manager and ADCETRIS Biomarker Lead, Diagnostics and Biomarkers, Seattle Genetics, Inc.

Shuji Ogino, MD, PhD, Professor (Pathology & Epidemiology), Brigham & Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health; Associate Member, Broad Institute of MIT and Harvard

Elena Orlando, PhD, Bioinformatics Investigator, Novartis Institutes for BioMedical Research

Adam C. Palmer, PhD, Postdoctoral Fellow, Harvard Program in Therapeutic Science, Harvard Medical School

Tushar Parlikar, PhD, Product Manager, Verily Life Sciences

Bakul Patel, Associate Director, Digital Health, FDA

Kinjal R. Patel, Senior Study Manager, Clinical Sciences, Bayer US

Tracy Petrie, PhD, MoleMapper Product Manager, Oregon Health & Science University

Robert Pierce, MD, Scientific Director, Immunopathology Core, Fred Hutchinson Cancer Research Center

Katerina Politi, PhD, Associate Professor, Pathology, Yale School of Medicine

George Poste, DVM, PhD, Chief Scientist, Complex Adaptive Systems, Regents’ Professor and Del E. Webb Chair in Health Innovation, Arizona State University

Osama Rahma, MD, Assistant Professor, Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Fred Ramsdell, PhD, Vice President, Research, Parker Institute for Cancer Immunotherapy

Susanne K. Rhoades, PhD, Director, Diagnostics Development, Tailored Therapeutics, Eli Lilly and Company

David L. Rimm, MD, PhD, Professor, Pathology, Yale University

Edwin Rock, MD, PhD, Vice President, Clinical Research, MacroGenics, Inc.

David B. Roth, MD, PhD, Simon Flexner Professor and Chair, Department of Pathology and Laboratory Medicine Director, Penn Center for Precision Medicine

Kurt Schalper, MD, PhD, Assistant Professor, Pathology and Medicine (Medical Oncology), Yale School of Medicine

Emmett Schmidt, MD, PhD, Scientific Associate Vice President, Merck Research Labs

Cecilia Schott, PharmD, MBA, Former Vice President, Precision Medicine, AstraZeneca Oncology Business Unit

Peter M. Shaw, PhD, Head, Clinical Pharmacogenetics, Merck

Daniel Stetson, PhD, Associate Principal Scientist, AstraZeneca

Ryan J. Sullivan, MD, Assistant Professor, Hematology & Oncology, Massachusetts General Hospital; Assistant Professor, Medicine, Harvard Medical School

Bakhos A. Tannous, PhD, Associate Professor, Neurology, Harvard Medical School; Director, Experimental Therapeutics and Molecular Imaging Lab; Director, Interdepartmental Neuroscience Center; Director, MGH Viral Vector Development Facility, Massachusetts General Hospital

Iman Tavassoly, MD, PhD, Research Fellow, Mount Sinai Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai

Raymond Tesi, MD, President and CEO, Acting CMO, INmune Bio

Elizabeth Thompson, MD, PhD, Assistant Professor, Pathology and Oncology, The Johns Hopkins University School of Medicine

Gregory Tsongalis, PhD, Professor, Pathology & Laboratory Medicine, Dartmouth College

Gabriel Vargas, MD, PhD, Executive Medical Director, Digital Health & Neuroscience Therapeutic Area Head, Early Development, Amgen

Dan E. Webster, PhD, Principal Scientist of Digital Health, Sage Bionetworks

Glen J. Weiss, MD, MBA, Director, Phase I Clinical Research, Beth Israel Deaconess Medical Center, Boston

Theresa L. Whiteside, PhD, Professor, Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute

Timothy Yap, MD, PhD, Associate Professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center

Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Early Clinical Oncology Development, Merck Research Labs